Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 131, Issue 2, Pages 300-313Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2012.06.048
Keywords
Atopic dermatitis; allergic contact dermatitis; contact hypersensitivity; irritant contact dermatitis; epidermal barrier; immune activation; T(H)2; T(H)17
Categories
Funding
- National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [5UL1RR024143-02]
- NIH Roadmap for Medical Research
- Dermatology Foundation Physician Scientist Career Development Award
- Centercore
- Eli Lilly
- Pfizer
- Amgen
- Merck
- Dermatology Foundation
- Regeneron
- Stiefel
Ask authors/readers for more resources
Atopic dermatitis (AD), as well as irritant contact dermatitis (ICD) and allergic contact dermatitis (ACD), are common skin diseases. These diseases are characterized by skin inflammation mediated by activated innate immunity or acquired immune mechanisms. Although AD, ICD, and ACD can be encountered in pure forms by allergists and dermatologists, patients with AD often present with increased frequency of ICD and ACD. Although a disturbed barrier alone could potentiate immune reactivity in patients with AD through increased antigen penetration, additional immune mechanisms might explain the increased susceptibility of atopic patients to ICD and ACD. This review discusses cellular pathways associated with increased skin inflammation in all 3 conditions and presents mechanisms that might contribute to the increased rate of ICD and ACD in patients with AD. (J Allergy Clin Immunol 2013;131:300-13.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available